Actively Recruiting
Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA
Led by Poznan University of Medical Sciences · Updated on 2026-02-04
96
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This randomized, double-blind, controlled trial is designed to compare the analgesic efficacy and safety of perineural dexamethasone versus perineural dexmedetomidine as adjuvants to ropivacaine for ultrasound-guided interspace between the popliteal artery and the capsule of the posterior knee (iPACK) and adductor canal blocks in patients undergoing primary unilateral total knee arthroplasty (TKA). Elderly participants scheduled for elective TKA will be randomized into three parallel groups: ropivacaine alone (control), ropivacaine combined with perineural dexamethasone, or ropivacaine combined with perineural dexmedetomidine. The primary objective is to determine whether the addition of either adjuvant reduces postoperative opioid consumption compared with ropivacaine alone and to assess potential differences in analgesic efficacy between the two adjuvants. Secondary outcomes include pain intensity at rest and during mobilization, time to first rescue analgesia, quality of early functional recovery, and the incidence of adverse events, including postoperative nausea and vomiting, motor impairment, and hemodynamic instability.
CONDITIONS
Official Title
Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 65 years or older
- Scheduled for primary unilateral total knee arthroplasty under standardized anesthetic protocol
- ASA physical status II-III (or I-III, depending on planning)
- Ability to understand the study procedures and provide written informed consent
You will not qualify if you...
- Contraindications to peripheral nerve blocks such as infection at injection site, coagulopathy, or patient refusal
- Known allergy or hypersensitivity to amide local anesthetics, dexamethasone, or dexmedetomidine
- Chronic opioid therapy or opioid use greater than 30 mg oral morphine equivalents per day in the last 3 months
- Severe liver or kidney impairment
- Significant cognitive impairment or inability to cooperate with pain assessment
- Participation in another interventional trial affecting pain or analgesic consumption
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Poznan University of Medical Sciences
Poznan, Poland, 62-701
Actively Recruiting
Research Team
M
Malgorzata Reysner, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here